Inhibitory effects of integrin avβ3 monoclonal antibody on implanted lesions of endometriosis model of SCID mouse

Abstract

Abstract: Objective To explore the potential use of integrin avβ3 (Lm609) monoclonal antibody against ectopic lesion and microvessel angiogenesis of human endometriosis xenografts in SCID mice. Methods The endometrial tissues from endometriosis patients were inoculated subcutaneously into SCID mouse, which were treated with Lm609, an inhibitor of angiogenesis, twice a week, for 3 weeks. The mice were sacrificed and immunohistochemical staining was employed to determine the microvessel density (MVD) and expression of integrin avβ3 in the lesion tissues. Results Lm609 inhibited the growth of the ectopic lesion. The lesion weighted 0.82±0.09 g in the treated group versus 0.51±0.93 g in the control group (P<0.05). The MVDs of the treated and control groups were 31.2±4.4 and 14.4±1.8 respectively (P<0.05). Conclusion Lm609 can inhibit the growth of ectopic lesion by reducing angiogenesis in SCID mouse.

CLC Number:

R711.71

ZHAO Jun¹, ZONG Li-li², LI Ya-li¹. Inhibitory effects of integrin avβ3 monoclonal antibody on implanted lesions of endometriosis model of SCID mouse[J]. Journal of Southern Medical University, 2005, 25(06): 709-711.

References

[1] Strathy JH, Molgaard CA, Coulam CB, et al. Endometriosis and infertility:a laparoscopic study of endometriosis among fertile and infertile women [J]. Fertil Steril, 1982, 38(6):667-72.
[2] Maas JWM, Le Noble FAC, Dunselman GAJ, et al. The chick embryo chorioallantoic membrane as a model to investigate the angiogenic properties of human endometrium [J]. Gynecol Obstet Invest, 1999, 48:108-12.
[3] Zamah NM, Dodson MG, Stephens LC, et al. Transplantation of normal and ectopic human endometrial tissue into athymic nude mice[J]. Am J Obstet Gynecol, 1984, 149:591-7.
[4] Blezinger P, Wang J. Systemic inhibition of tumor growth and tumor metastases by intramuscular administration of the endostatin gene[J]. Nat Biotechnol, 1999, 17(4):343-8.
[5] Breasalier RS, HO SB, Schoeppner HL, et al. Enhanced salvation of mucin-associated carbohydrate structures in human colon cancer metastasis [J]. Gastroenterology, 1996, 110(5):1354-67.
[6] Horton MA. The alpha v beta 3 integrin "vitronectin receptor" [J].Int J Biochem Cell Biol, 1997, 29721-5.
[7] Eliceiri BP, Cheresh DA. Role of alpha v integrins during angiogenesis[J]. Cancer J, 2000, 63:S245-9.
[8] Brooks PC, Stromblad S, Klemke R, et al. Antiintegrin alpha v beta 3 blocks human breast cancer growth and angiogenesis in human skin[J]. J Clin Invest, 1995, 96:1815-22.
[9] Hii LL, Rogers PA. Endometrial vascular and glandular:expression of integrin alpha(v) beta3 in women with and without endometriosis[J]. Hum Reprod, 1998, 13(4):1030-5.
[10] Gutheil JC, Campbell TN, Pierce PR, et al. Targeted antiangiogenic therapy for cancer using Vitaxin:a humanized monoclonal antibody to the integrin alpha v beta3 [J]. Clin Cancer Res, 2000, 6 (8):3056-61.
[11] Sparano JA, Bernardo P, Stephenson P, et al. Randomized phase Ⅲtrial of marimastat versus placebo in patients with metastatic breast cancer who have responding or stable disease after first-line chemotherapy:Eastern Cooperative Oncology Group trial E2196[J]. J Clin Oncol, 2004, 22:4683-90.